3月21日，内地生物制药公司维昇药业-B（02561）在港交所主板挂牌上市，然而开市后不久，该股便出现大幅下跌。盘中数据显示，维昇药业-B股价大跌5.52%，引发市场关注。
根据此前公告，维昇药业-B以每股68.8港元的价格完成招股，募集资金净额约6.72亿港元。公司香港公开发售部分获得71.64倍超额认购，认购一手（100股）的中签率为6.27%，显示出投资者对该股的初步热情。然而，上市首日的股价表现却未能延续这一热度。
分析人士指出，维昇药业-B上市首日的大幅下跌可能反映了投资者情绪的快速转变。尽管公司在招股阶段获得高度超额认购，但上市后的抛售压力可能源于短期投资者的获利了结，以及市场对公司估值的重新评估。此外，生物医药行业的整体市场环境和投资者风险偏好的变化也可能是导致股价下跌的因素之一。投资者需密切关注公司后续的经营表现和行业动态，以评估其长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.